ALIM vs. ATOS, VERU, LFCR, TRVI, OMER, ZVRA, RIGL, OGI, SKYE, and IVA
Should you be buying Alimera Sciences stock or one of its competitors? The main competitors of Alimera Sciences include Atossa Therapeutics (ATOS), Veru (VERU), Lifecore Biomedical (LFCR), Trevi Therapeutics (TRVI), Omeros (OMER), Zevra Therapeutics (ZVRA), Rigel Pharmaceuticals (RIGL), Organigram (OGI), Skye Bioscience (SKYE), and Inventiva (IVA). These companies are all part of the "pharmaceutical preparations" industry.
Alimera Sciences (NASDAQ:ALIM) and Atossa Therapeutics (NASDAQ:ATOS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.
Alimera Sciences has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, Atossa Therapeutics has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.
Atossa Therapeutics has a net margin of 0.00% compared to Alimera Sciences' net margin of -24.93%. Atossa Therapeutics' return on equity of -31.01% beat Alimera Sciences' return on equity.
In the previous week, Alimera Sciences and Alimera Sciences both had 2 articles in the media. Atossa Therapeutics' average media sentiment score of 0.03 beat Alimera Sciences' score of 0.00 indicating that Atossa Therapeutics is being referred to more favorably in the news media.
99.8% of Alimera Sciences shares are owned by institutional investors. Comparatively, 12.7% of Atossa Therapeutics shares are owned by institutional investors. 31.4% of Alimera Sciences shares are owned by company insiders. Comparatively, 7.8% of Atossa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Alimera Sciences received 127 more outperform votes than Atossa Therapeutics when rated by MarketBeat users. However, 64.96% of users gave Atossa Therapeutics an outperform vote while only 57.72% of users gave Alimera Sciences an outperform vote.
Alimera Sciences has higher revenue and earnings than Atossa Therapeutics. Atossa Therapeutics is trading at a lower price-to-earnings ratio than Alimera Sciences, indicating that it is currently the more affordable of the two stocks.
Alimera Sciences currently has a consensus price target of $7.50, suggesting a potential upside of 114.90%. Atossa Therapeutics has a consensus price target of $4.50, suggesting a potential upside of 194.12%. Given Atossa Therapeutics' higher probable upside, analysts clearly believe Atossa Therapeutics is more favorable than Alimera Sciences.
Summary
Alimera Sciences beats Atossa Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Alimera Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALIM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alimera Sciences Competitors List
Related Companies and Tools
